{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T20:45:15Z","timestamp":1770583515311,"version":"3.49.0"},"reference-count":14,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,4,23]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>A woman in her late 50s presented to the ophthalmology clinic having bilateral eye pain and discharge for the last month. Her medical history was significant for lung adenocarcinoma, for which she was being treated with nivolumab. Filamentary keratitis was evident at the slit-lamp examination. Regardless of ophthalmic reasons, nivolumab was suspended. Prednisolone ointment was started, with a complete remission. We present a case of steroid-responsive filamentary keratitis triggered by nivolumab. We aim to highlight the importance of prompt ophthalmology referral and the use of therapies targeting ocular surface inflammation in immune checkpoint inhibition therapy.<\/jats:p>","DOI":"10.1136\/bcr-2023-258013","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T11:56:58Z","timestamp":1714478218000},"page":"e258013","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Nivolumab-associated immune-related filamentary keratitis"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2756-9145","authenticated-orcid":false,"given":"Maria","family":"Madeira","sequence":"first","affiliation":[{"name":"Ophthalmology, Centro Hospitalar de Lisboa Ocidental EPE Hospital de Egas Moniz, Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Ophthalmology, Centro Hospitalar de Lisboa Ocidental EPE Hospital de Egas Moniz, Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Filipe","sequence":"additional","affiliation":[{"name":"Ophthalmology, Centro Hospitalar de Lisboa Ocidental EPE Hospital de Egas Moniz, Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"2025082708581338000_17.4.e258013.1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"CHECKPOINT INHIBITOR IMMUNE THERAPY: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"2025082708581338000_17.4.e258013.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025082708581338000_17.4.e258013.3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002119","article-title":"Ocular adverse events in PD-1 and PD-L1 inhibitors","volume":"9","author":"Young","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025082708581338000_17.4.e258013.4","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11174993","article-title":"Ocular inflammation induced by immune Checkpoint inhibitors","volume":"11","author":"Chaudot","year":"2022","journal-title":"J Clin Med"},{"key":"2025082708581338000_17.4.e258013.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2022.101686","article-title":"Bilateral corneal Perforation in Ipilimumab\/Nivolumab - associated peripheral ulcerative Keratitis","volume":"28","author":"Aschauer","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2025082708581338000_17.4.e258013.6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajoc.2019.01.013","article-title":"Corneal ulceration associated with Nivolumab use","volume":"14","author":"Parker","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2025082708581338000_17.4.e258013.7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/ICO.0000000000002460","article-title":"Nivolumab-induced ulcerative Keratitis-A case report","volume":"40","author":"Losonczy","year":"2021","journal-title":"Cornea"},{"key":"2025082708581338000_17.4.e258013.8","doi-asserted-by":"crossref","first-page":"1021713","DOI":"10.3389\/fonc.2022.1021713","article-title":"Immune-related Keratitis is a rare complication associated with Nivolumab treatment in a patient with advanced colorectal cancer: A case report","volume":"12","author":"Su","year":"2022","journal-title":"Front Oncol"},{"key":"2025082708581338000_17.4.e258013.9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ICO.0000000000000724","article-title":"Cyclosporine for dry eye associated with Nivolumab: A case progressing to corneal Perforation","volume":"35","author":"Nguyen","year":"2016","journal-title":"Cornea"},{"key":"2025082708581338000_17.4.e258013.10","article-title":"Bilateral uveitis and Keratitis following Nivolumab treatment for metastatic Melanoma","volume":"3","author":"Baughman","year":"2017","journal-title":"Med Case Rep (Wilmington)"},{"key":"2025082708581338000_17.4.e258013.11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2016.10.008","article-title":"Corneal graft rejection in a patient treated with Nivolumab for primary lung cancer","volume":"102","author":"Le Fournis","year":"2016","journal-title":"Lung Cancer"},{"key":"2025082708581338000_17.4.e258013.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2020.100691","article-title":"Bilateral uveitis associated with Nivolumab therapy for metastatic non-small cell lung cancer","volume":"18","author":"Dermarkarian","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2025082708581338000_17.4.e258013.13","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2397"},{"key":"2025082708581338000_17.4.e258013.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-258013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:58:18Z","timestamp":1756310298000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-258013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,30]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bcr-2023-258013"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-258013","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}